These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35688367)

  • 1. Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
    Scanio MJC; Searle XB; Liu B; Koenig JR; Altenbach RJ; Gfesser GA; Bogdan A; Greszler S; Zhao G; Singh A; Fan Y; Swensen AM; Vortherms T; Manelli A; Balut C; Gao W; Yong H; Schrimpf M; Tse C; Kym P; Wang X
    Bioorg Med Chem Lett; 2022 Sep; 72():128843. PubMed ID: 35688367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.
    Pizzonero M; Akkari R; Bock X; Gosmini R; De Lemos E; Duthion B; Newsome G; Mai TT; Roques V; Jary H; Lefrancois JM; Cherel L; Quenehen V; Babel M; Merayo N; Bienvenu N; Mammoliti O; Coti G; Palisse A; Cowart M; Shrestha A; Greszler S; Van Der Plas S; Jansen K; Claes P; Jans M; Gees M; Borgonovi M; De Wilde G; Conrath K
    J Med Chem; 2024 Apr; 67(7):5216-5232. PubMed ID: 38527911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
    Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
    Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.
    Scanio MJC; Searle XB; Liu B; Koenig JR; Altenbach R; Gfesser GA; Bogdan A; Greszler S; Zhao G; Singh A; Fan Y; Swensen AM; Vortherms T; Manelli A; Balut C; Jia Y; Gao W; Yong H; Schrimpf M; Tse C; Kym P; Wang X
    ACS Med Chem Lett; 2019 Nov; 10(11):1543-1548. PubMed ID: 31749908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
    Bongiorno R; Ludovico A; Moran O; Baroni D
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors.
    Righetti G; Casale M; Liessi N; Tasso B; Salis A; Tonelli M; Millo E; Pedemonte N; Fossa P; Cichero E
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane regulator correctors and potentiators.
    Rowe SM; Verkman AS
    Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23818513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222.
    Singh AK; Fan Y; Balut C; Alani S; Manelli AM; Swensen AM; Jia Y; Neelands TR; Vortherms TA; Liu B; Searle XB; Wang X; Gao W; Hwang TC; Ren HY; Cyr D; Kym PR; Conrath K; Tse C
    J Pharmacol Exp Ther; 2020 Jan; 372(1):107-118. PubMed ID: 31732698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.
    Galietta LJ
    Paediatr Drugs; 2013 Oct; 15(5):393-402. PubMed ID: 23757197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis.
    Wang X; Liu B; Searle X; Yeung C; Bogdan A; Greszler S; Singh A; Fan Y; Swensen AM; Vortherms T; Balut C; Jia Y; Desino K; Gao W; Yong H; Tse C; Kym P
    J Med Chem; 2018 Feb; 61(4):1436-1449. PubMed ID: 29251932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
    Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
    Vaccarin C; Veit G; Hegedus T; Torres O; Chilin A; Lukacs GL; Marzaro G
    J Med Chem; 2024 Aug; 67(16):13891-13908. PubMed ID: 39137389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.